[1] Ando M, Okamoto I, Yamamoto N, et al.Predictive factors for interstitial lung disease, antitumor response,and survival in non-small-cell lung cancer patients treated with gefitinib[J]. J Clin Oncol, 2006,24:2549-2556.
[2] Namba T, Tanaka K, Hoshino T, et al. Suppression of expression of heat shock protein 70 by gefitinib and its contribution to pulmonary fibrosis[J]. PLoS One,2011,6(11):e27296.
[3] Hotta K, Kiura K, Tabata M, et al.Interstitial lung disease in Japanese patients with non-small cell lung cancer receiving gefitinib: an analysis of risk factors and treatment outcomes in Okayama Lung Cancer Study Group[J]. Cancer J, 2005,11(5):417-424.
[4] Kitajima H, Takahashi H, Harada K, et al.Gefitinib-induced interstitial lung disease showing improvement after cessation: disassociation of serum markers[J]. Respirology,2006, 11(2):217-220.
[5] 具海月,蔡祖龙,赵绍宏,等.分子靶向治疗后肾透明细胞癌肺转移灶囊样薄壁空洞形成(附2例报告及文献复习)[J].实用放射学杂志,2008, 24(4): 472 - 474.
[6] 黄贤会, 张丽红, 李玉平. 肺空洞型转移瘤CT诊断[ J]. 医学影像学杂志, 2007, 17(4): 363 - 365.
[7] 陈建华. 肺转移瘤的特殊CT 表现[ J]. 实用医技杂志, 2004, 11(10) : 2101 - 2102. |
